- Home
- JUNS vs EVAX Comparison
JUNS vs EVAX Comparison
Compare JUNS & EVAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- JUNS
- EVAX
- Stock Information
- Founded
- JUNS 2015
- EVAX 2008
- Country
- JUNS United States
- EVAX Denmark
- Employees
- JUNS N/A
- EVAX N/A
- Industry
- JUNS
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- JUNS
- EVAX Health Care
- Exchange
- JUNS NYSE
- EVAX Nasdaq
- Market Cap
- JUNS 17.6M
- EVAX 16.3M
- IPO Year
- JUNS 2024
- EVAX 2021
- Fundamental
- Price
- JUNS $0.62
- EVAX $1.31
- Analyst Decision
- JUNS
- EVAX Strong Buy
- Analyst Count
- JUNS 0
- EVAX 2
- Target Price
- JUNS N/A
- EVAX $10.00
- AVG Volume (30 Days)
- JUNS 146.8K
- EVAX 74.6K
- Earning Date
- JUNS 05-11-2025
- EVAX 05-27-2025
- Dividend Yield
- JUNS N/A
- EVAX N/A
- EPS Growth
- JUNS N/A
- EVAX N/A
- EPS
- JUNS N/A
- EVAX N/A
- Revenue
- JUNS N/A
- EVAX $3,344,000.00
- Revenue This Year
- JUNS N/A
- EVAX $102.45
- Revenue Next Year
- JUNS N/A
- EVAX $100.30
- P/E Ratio
- JUNS N/A
- EVAX N/A
- Revenue Growth
- JUNS N/A
- EVAX 4480.82
- 52 Week Low
- JUNS $0.51
- EVAX $1.20
- 52 Week High
- JUNS $19.51
- EVAX $22.05
- Technical
- Relative Strength Index (RSI)
- JUNS N/A
- EVAX 29.55
- Support Level
- JUNS N/A
- EVAX $1.20
- Resistance Level
- JUNS N/A
- EVAX $1.46
- Average True Range (ATR)
- JUNS 0.00
- EVAX 0.13
- MACD
- JUNS 0.00
- EVAX 0.01
- Stochastic Oscillator
- JUNS 0.00
- EVAX 16.52
About JUNS JUPITER NEUROSCIENCES INC
Jupiter Neurosciences Inc is a clinical-stage research and development pharmaceutical company located in Jupiter, Florida. The company has developed a resveratrol platform product that targets the treatment of neuro-inflammation. Its platform product, JOTROL, offers potential therapeutic benefit to the majority of central nervous system diseases such as Alzheimer's disease, ataxias, and metabolic disorders such as Lysosomal Storage Disorders and mitochondrial diseases.
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.